

Participant Eligibility

KEY INCLUSION CRITERIA

Please consider referring any patient who meets the following criteria:

- Adults (40-80 years of age)
- Severe emphysema
- Stopped smoking (>8 weeks)
- Have at least one clear target lobe with:
- ≥50% destruction at -910HU, and
- incomplete adjacent fissure (≥80%), and
- heterogenous emphysema (defined as ≥15% difference between the target lobe and the ipsilateral lobe)
- Collateral ventilation confirmed by the Chartis[®] System
- 6MWD ≥150m and ≤450m
- Pulmonary rehab completed within
 12 months of enrollment




Please refer to the **CONVERT II**Pocket Guide to help identify appropriate patients.

KEY EXCLUSION CRITERIA

Please note that if your patient presents with any of the following, he or she is not an appropriate candidate for the CONVERT II Trial:

- Prior LVRS, lobectomy or pneumonectomy, lung transplantation
- 3 or more COPD exacerbations requiring hospitalization within the last 12 months
- Asthma or chronic bronchitis as the primary diagnosis
- Ongoing active respiratory infection
- Requires invasive ventilatory support
- Pulmonary hypertension
- Alpha-1-antitrypsin deficiency



CONVERT II is currently enrolling patients in sites around the world.



Please visit pulmonx.com/active-clinical-trials/ to contact a site near you.



Pulmonx Corporation, 700 Chesapeake Drive, Redwood City, CA 94063

© 2025 Pulmonx Corporation or its affiliates. All rights reserved.

All trademarks herein are the property of Pulmonx Corporation and its affiliate CONVERT II trial brochure: GI O-FN-2302-v3



CONVERT II Clinical Trial

A trial to evaluate the safety and effectiveness of AeriSeal® System to block collateral ventilation (CV) and convert a severe emphysema patient from CV+ to CV- status.



CAUTION - Investigational device. Limited by Federal law to investigational use.

The AeriSeal System is under investigation in the US and its use is limited to this trial.

AeriSeal System has received CE Mark in Europe and registration from Australian TGA.

This brochure is for physician use only. Not approved by ethics committee for distribution opatients.







THE GOAL

The objective of the CONVERT II
Pivotal Trial is to establish the
safety and effectiveness of using
the AeriSeal® System to target and
treat the fissural defects that cause
collateral ventilation between lung
lobes, which preclude some severe
COPD/emphysema patients from
benefiting from minimally invasive
bronchoscopic lung volume reduction
(BLVR) treatment with Zephyr® Valves.

The CONVERT II Trial will complement the results gained in the CONVERT Trial. (ClinicalTrials.gov Identifier: NCT04559464).

You likely have patients who could be eligible for and benefit from participating in the CONVERT II trial. →

METHODS

The CONVERT II Trial (NCT06035120) is a multicenter, prospective, single-arm, pivotal study conducted by Pulmonx Corporation.

PATIENTS WILL BE ENROLLED

STUDY CENTERS ACROSS THE US, EU AND AUSTRALIA


YEAR FOLLOW-UP

AeriSeal System
INVESTIGATIONAL DEVICE IN THE US

CONVERT II Trial

STUDY DESIGN

Participants will be evaluated at 14 visits (9 in clinic and 5 via phone) over 2½ years. In addition, pulmonary rehab must be completed within 12 months of enrollment and following treatment with Zephyr Valves.



INFORMED CONSENT

Initial CONVERT Trial¹

ABOUT

A multicenter, prospective, single-arm study is being conducted at 14 clinical centers across Europe and Australia to evaluate AeriSeal System to occlude collateral channels to convert a CV+ lung lobe to having little to no CV-.

A secondary objective is Zephyr Valve treatment in the CV- converted patients and assessment of clinical outcomes.

Enrollment has been completed and patients are being followed through 1 year post-Zephyr Valve Treatment.



INTERIM RESULTS

CONVERT Trial (NCT04559464)

CONVERT

PATIENTS
ENROLLED AT
14 OUS SITES

CONVERSION RATE (75/97)

TLVR MCID -350ML 45 DAYS POST-ZV (62/70)

SAE REPORTED THROUGH 12 MONTHS, INCLUDED:

Inflammatory response (post-AS)	15.7%
COPD exacerbation	10.89
Pneumonia	9.89
Pneumonitis	5.9%
Pneumothorax (post-ZV)	21.19
Death (9 months post-ZV)	19